Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians, an independent physician association serving managed care populations across Los Angeles and Orange counties, will provide coverage for the company’s Epi+Gen CHD and PrecisionCHD tests for eligible members with prior authorization. This coverage expands access to physician-ordered blood tests designed to assess coronary heart disease risk and support diagnosis and personalized treatment planning.
The Epi+Gen CHD test evaluates a patient’s three-year risk of a coronary heart disease event, while PrecisionCHD helps diagnose coronary heart disease and identify its underlying molecular drivers, according to Cardio Diagnostics. Both tests are noninvasive blood-based diagnostics that do not require fasting or radiation exposure, supporting broader adoption of precision cardiovascular medicine across community healthcare networks.
This announcement matters because cardiovascular disease remains the leading cause of death globally, and early detection and personalized treatment are critical to improving outcomes. By integrating these advanced tests into Atlas Healthcare Physicians’ coverage, more patients in Southern California’s managed care populations will have access to cutting-edge diagnostics that can identify risk years before a cardiac event occurs. The tests’ noninvasive nature and lack of fasting requirements could lower barriers to screening, potentially increasing compliance and early intervention.
For the healthcare industry, this partnership underscores a growing trend toward precision medicine, where treatments are tailored to individual genetic and epigenetic profiles. Cardio Diagnostics’ AI-driven Integrated Genetic-Epigenetic Engine forms the core technology behind these tests, enabling more accurate risk stratification and diagnosis than traditional methods. As managed care organizations and independent physician associations adopt such technologies, the standard of care may shift toward more personalized approaches, potentially reducing healthcare costs associated with late-stage cardiovascular disease.
For investors, the expansion of coverage through Atlas Healthcare Physicians signals growing commercial traction for Cardio Diagnostics’ products. The company’s ability to secure coverage from a major IPA in a large metropolitan market like Los Angeles and Orange counties could pave the way for additional partnerships and broader reimbursement. According to the press release, the latest news and updates relating to CDIO are available in the company’s newsroom at https://nnw.fm/CDIO.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary AI-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease. For more information, visit the full press release at https://nnw.fm/EFQen.
